OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

OBI Eligible to Receive Milestone Payments as well as US$3.0 Million Upfront Cash Payment and Royalties on Sales in Taiwan. DIFICID was approved in 2012 by Taiwan’s Department of Health to Treat Clostridium Difficile-Associated Diarrhea (CDAD) TAIPEI, October 5, 2015/ — OBI Pharma, Inc. (TPex: 4174) today announced an agreement with MSD, known as Merck […]

HOMEWhat’s NewNewsOBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2015.Aug.31

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

2016.Feb.21

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer